Today, a Director at IsoRay (ISR), Philip Vitale, bought shares of ISR for $12.9K.
This recent transaction increases Philip Vitale’s holding in the company by 37.5% to a total of $43.23K.
See today’s analyst top recommended stocks >>
Based on IsoRay’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $1.56 million and GAAP net loss of $1.51 million. In comparison, last year the company earned revenue of $1.21 million and had a GAAP net loss of $1.55 million. Currently, IsoRay has an average volume of 236.8K.
Philip Vitale’s trades have generated a -30.8% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.
